Fortrea CEO Anshul Thakral said demand is picking up across early-phase, biotech and biopharma work, with biotech still a growth driver. The company made a modest backlog adjustment to better reflect the rest-of-life revenue on its contracts. It also closed its Texas site acquisition, which adds a 200-bed facility.
FTRE · Fortrea Holdings Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Fortrea's revenues were $2,006.2 for the nine months ended September 30, 2026, down 2.7% from $2,062.9, and $691.5 for the quarter, down 1.4%. Backlog was $7.3 billion as of September 30, 2026, after a reduction of approximately $558 for estimated scope and study delivery changes. It also completed the acquisition of the Early Phase Services division of Worldwide Clinical Trials on October 19, 2026 for aggregate consideration of approximately $45.0.
Fortrea reported third-quarter 2026 revenue of $691.5 million and adjusted EBITDA of $58.0 million, raised full-year revenue and adjusted EBITDA guidance midpoints, and expects positive free cash flow in the fourth quarter and full year.
Fortrea reported third-quarter revenue of $691.5 million, GAAP net income of $0.6 million and adjusted EBITDA of $58.0 million for the quarter ended September 30, 2026. It raised full-year 2026 guidance and reduced backlog by $558 million.
Fortrea Holdings Inc. appointed Carrie Russell Chief Accounting Officer effective October 5, 2026, with a $340,000 annual base salary and a 40% annual incentive bonus target.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Fortrea reported Q2 2026 revenue of $678.2 million (down 4.5% YoY) and adjusted EBITDA of $58.7 million (up from $54.9M), raised full-year 2026 guidance, and booked $720.4M in net new business with a 1.06x book-to-bill, but its newly appointed CFO was placed on leave amid litigation tied to his prior employer, prompting an interim CFO appointment.
- + Raised full-year 2026 revenue guidance to $2.62B-$2.69B and adjusted EBITDA to $205M-$220M.
- + Q2 book-to-bill of 1.06x with fourth consecutive quarter above 1.0x and trailing 12-month of 1.12x; first-half net new business awards up 19% YoY.
- + Q2 adjusted EBITDA grew to $58.7M from $54.9M on cost savings and operational efficiencies.
- + Operating cash flow improved to $28.9M (from $21.8M) and free cash flow to $19.9M (from $14.3M), with no revolver borrowings.
- − Q2 revenue declined 4.5% YoY to $678.2M due to lower pass-throughs and FSP headwinds.
- − Newly appointed CFO Jason Knoblauch placed on paid leave after a Delaware court granted a TRO tied to alleged restrictive covenant violations by his prior employer.
- − Q2 GAAP net loss of $(13.2)M with $(0.14) diluted loss per share.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted basic EPS non-GAAP | $0.7 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted diluted EPS non-GAAP | $0.66 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $217.7M | Trailing Twelve Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $65.8M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| backlog | 7.32B | as of September 30, 2026 | — |
| Free cash flow non-GAAP | $47.4M | Nine Months Ended September 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FTRE
this stock
Fortrea Holdings Inc.
|
$1.98B | +18.8% | +1.0% | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 18
Fortrea CEO Anshul Thakral said demand is picking up across early-phase, biotech and biopharma work, with biotech still a growth driver. The company made a modest backlog adjustment to better reflect the rest-of-life revenue on its contracts. It also closed its Texas site acquisition, which adds a 200-bed facility.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FTRE | +0.6% | -14.8% | +33.2% | -3.7% | +18.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +4.5% | -9.3% | +36.7% | -0.3% | +11.8% |